A79809
5-Aminosalicylic acid
95%
Synonym(s):
5-AS, 5-Amino-2-hydroxybenzoic acid, Mesalamine
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
H2NC6H3-2-(OH)CO2H
CAS Number:
Molecular Weight:
153.14
UNSPSC Code:
12352106
NACRES:
NA.22
PubChem Substance ID:
EC Number:
201-919-1
Beilstein/REAXYS Number:
2090421
MDL number:
assay
95%
form
powder with small lumps
reaction suitability
reaction type: solution phase peptide synthesis
mp
275-280 °C (dec.) (lit.)
application(s)
detection
peptide synthesis
SMILES string
Nc1ccc(O)c(c1)C(O)=O
InChI
1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)
InChI key
KBOPZPXVLCULAV-UHFFFAOYSA-N
Gene Information
human ... ALOX5(240), PPARG(5468), PTGS1(5742), PTGS2(5743)
Application
5-Aminosalicylic acid is a peroxidase substrate suitable for use in ELISA procedures. This substrate produces a soluble end product that is brown in color and can be read spectrophotometrically at 450 nm. The reaction may be stopped with 3 N NaOH and read at 550 nm.
Still not finding the right product?
Explore all of our products under 5-Aminosalicylic acid
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
target_organs
Respiratory system
Storage Class
13 - Non Combustible Solids
wgk
WGK 2
flash_point_f
No data available
flash_point_c
No data available
ppe
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Mirjana Rajilić-Stojanović et al.
Inflammatory bowel diseases, 19(3), 481-488 (2013-02-07)
Presence of intestinal microbes is a prerequisite for the development of ulcerative colitis (UC), although deviation of the normal intestinal microbiota composition, dysbiosis, is presumably implicated in the etiology of UC. The fecal microbiota of 30 UC samples obtained from
Christian P Selinger et al.
Inflammatory bowel diseases, 19(10), 2199-2206 (2013-08-01)
Poor adherence frequently impaired the efficacy of therapy to maintain remission from inflammatory bowel diseases (IBD). There is a lack of practical and effective interventions to improve adherence. This study aimed to identify modifiable risk factors, which may yield targets
W Kruis et al.
Alimentary pharmacology & therapeutics, 37(7), 680-690 (2013-02-19)
Robust evidence regarding medical intervention for symptomatic uncomplicated colonic diverticular disease (DD) is sparse. To investigate mesalazine (Salofalk granules) in this setting. In a double-blind, placebo-controlled, multicentre, 6-week trial, patients were randomised to mesalazine 1000 mg three times daily or placebo.
Global Trade Item Number
| SKU | GTIN |
|---|---|
| A79809-5G | 04061833390887 |
| A79809-100G | 04061833390870 |